Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jiangsu Cowin Biotech Co (SHSE:688426) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Jiangsu Cowin Biotech Co EBITDA Margin % Related Terms
Jiangsu Cowin Biotech Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688426 vs VRTX, REGN, RVMD: EBITDA Margin % Comparison
For the Biotechnology subindustry, Jiangsu Cowin Biotech Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jiangsu Cowin Biotech Co EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Jiangsu Cowin Biotech Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Jiangsu Cowin Biotech Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jiangsu Cowin Biotech Co (SHSE:688426) has a EBITDA Margin % of -28.93% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Jiangsu Cowin Biotech Co and its competitors. According to the industry distribution chart, Jiangsu Cowin Biotech Co ranks #443 out of 940 companies in the Biotechnology industry, placing it in the top 47.1%.
Is Jiangsu Cowin Biotech Co's EBITDA Margin % too high?
Jiangsu Cowin Biotech Co's current EBITDA Margin % is -28.93%. Based on the distribution chart, Jiangsu Cowin Biotech Co ranks #443 out of 940 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Jiangsu Cowin Biotech Co has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Jiangsu Cowin Biotech Co's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Jiangsu Cowin Biotech Co ranks #443 out of 940 companies for EBITDA Margin %. This puts Jiangsu Cowin Biotech Co in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Jiangsu Cowin Biotech Co and its competitors. Jiangsu Cowin Biotech Co's current EBITDA Margin % is -28.93%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangsu Cowin Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Jiangsu Cowin Biotech Co (SHSE:688426) is currently considered Possible Value Trap. The stock's GF Value™ is ¥29.27, compared to a current price of ¥15.30 — trading 47.7% below its estimated fair value. The current EBITDA Margin % is -28.93%. Jiangsu Cowin Biotech Co's overall GF Score™ is 63/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Jiangsu Cowin Biotech Co (SHSE:688426), the current EBITDA Margin % is -28.93% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jiangsu Cowin Biotech Co (SHSE:688426) Overvalued in 2026?
Based on GuruFocus' analysis, Jiangsu Cowin Biotech Co stock appears to be undervalued.
The current stock price of ¥15.30 is trading 47.7% below its estimated GF Value™ of ¥29.27.
GuruFocus considers Jiangsu Cowin Biotech Co to be Possible Value Trap.
Key valuation signals for SHSE:688426:
EBITDA Margin %: -28.93%
GF Value™: ¥29.27 vs. price of ¥15.30 (47.7% below fair value)
No single metric tells the full story. See the SHSE:688426 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jiangsu Cowin Biotech Co Ltd is a national high-tech enterprise with independent intellectual property rights based in the field of life sciences. It provides innovative biological products and services to in vitro diagnostic users. The product line mainly includes molecular diagnostic raw materials enzymes, nucleic acid collection and protection agents, nucleic acid extraction kits, molecular diagnostic detection reagents and others.
63GF Score
Get the complete analysis for SHSE:688426
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688426 has been successfully added to your 
